Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Coeur Commences Drilling at Silver North's Tim Project (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Bioasis Technologies Inc.
V.BTI
Alternate Symbol(s):
BIOAF
Healthcare
Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to...
develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
TSXV:BTI - Post Discussion
Bioasis Technologies Inc.
> Chart of the day!!!!!!!!!!!!!!!! Prothena.
New Post
View:
Discussion
List
(13)
•••
narmac
X
View Profile
View Bullboard History
Post by
narmac
on Sep 03, 2021 7:38am
Chart of the day!!!!!!!!!!!!!!!! Prothena.
Chart of the Day: Prothena
September 2, 2021: Published by Barchart.com
The Barchart Chart of the Day
belongs to the biomedical company
Prothena (NASDAQ:
PRTA
). I found the stock by sorting
Barchart's Top 100 Stocks list
first by the most frequent number of new highs in the last month then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Spotter signaled a buy on 8/5 the stock gained 28.58%.
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; A, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Prothena Corporation plc
77 Sir John Rogersons QuayBlock C Grand Canal DocklandsDublin 2Ireland
353 1 236 2500
https://www.prothena.com
Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 20 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the
Barchart.com
website when you read this report.
Barchart technical indicators:
100% technical buy signals
254.22+ Weighted Alpha
469.97% gain in the last year
Trend Spotter buy signal
Above its 20, 50 and 100 day moving averages
15 new highs and up 36.39% in the last month
Technical support level at 70.22
Recently traded at 71.93 with a 50 day moving average of 56.22
Fundamental factors:
Market Cap $3.10 billion
Revenue and Earnings are all over the charts
Wall Street analysts issued 5 strong buy and 7 buy recommendations on the stock
TipRanks experts rate the stock 10/10
4,970 investors are monitoring the stock on Seeking Alpha
The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stock are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance and reevaluate your stop losses at least on a weekly basis.
Disclosure:
I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in PRTA, over the next 72 hours.
More on this symbol:
·
QUOTES
·
Overview
·
Performance Report
·
CHARTS
·
Interactive Chart
·
Technical Chart
·
TECHNICALS
·
Technical Analysis
·
Trader’s Cheat Sheet
·
Barchart Opinion
·
Trading Strategies
·
Price History
·
OPTIONS
·
Options Quotes
·
Volatility & Greeks
·
Covered Calls
·
Naked Puts
·
Option Spreads
·
COMPANY
·
News
·
Profile
·
SEC Filings
·
Competitors
·
Stock Comparison
·
ANALYSTS
·
Earnings Estimates
·
Analyst Ratings
·
FINANCIALS
·
Income Statement
·
Cash Flow
·
Balance Sheet
·
ARCHIVE
·
Past Reports
(1380)
•••
prophetoffacts
X
View Profile
View Bullboard History
Comment by
prophetoffacts
on Sep 03, 2021 9:24am
This post has been removed in accordance with Community Policy
(2401)
•••
JDavenport
X
View Profile
View Bullboard History
Comment by
JDavenport
on Sep 03, 2021 10:55am
So, profitoffacts, fit this article into your discussion of Prothena. Is there a case to be made that PRX012 might be, could be, an xB3 drug? Do a search on when PRX012 was first revealed? Interesting? No? How does the information in the article fit with Bioasis's very much confusing March/21 goings-on with Prothena's options extensions? Why is so low a dose of PRX012 needed
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
A New Clean Technology for Recovering Precious Metals From End of Life Products